Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tislelizumab + bevacizumab + chemotherapy in second-line RAS-mutant metastatic colorectal cancer
ChiCTR2200062758Phase 2Not yet recruiting
- Sponsor
- Chongqing University
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, bevacizumab, mFOLFOX6 and FOLFIRI in colorectal cancer (CRC), sponsored by Chongqing University. Primary endpoints: Safety and Objective response rate. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
tislelizumabbevacizumabmFOLFOX6FOLFIRI
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200062758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062758.